Infinity To Use Medidata RBM in Phase III Oncology Study

Published on: 

Applied Clinical Trials

Infinity Pharmaceuticals will use Medidata's RBM solution in an upcoming Phase III oncology study for patients with indolent non-Hodgkin lymphoma.

Infinity Pharmaceuticals has expanded its use of the Medidata Clinical Cloud®, by utilizing its risk-based monitoring (RBM) solution in an upcoming Phase III oncology study for patients with indolent non-Hodgkin lymphoma.

Infinity has been a Medidata customer since 2005, utilizing the company’s cloud-based technology for electronic data capture and management (Medidata Rave®) and medical coding (Medidata Coder®) across its pre-clinical and Phase I-III development programs. To further advance its drug development strategy and outsourcing model, Infinity is leveraging the combination of technology and analytics within Medidata RBM-including centralized statistical analytics, targeted source document verification (TSDV), and study and site level key risk indicators (KRIs).

Advertisement

Read the full release.